NCT06684184

Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)

Safety and Efficacy of Blinatumomab in Refractory Myasthenia Gravis

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Zhongming Qiu · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluating the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis and exploring the immunological mechanisms of Blinatumomab therapy in refractory myasthenia gravis. The main questions it aims to answer are: Will Blinatumomab improve the symptoms of participants? What medical problems do participants have when using Blinatumomab? Participants will: Continuous intravenous infusion of Blinatumomab for 5 days, pause for one week, and continue continuous intravenous infusion for 5 days Visit the clinic once every 1 month for checkups and tests Keep a diary of their symptoms

Conditions

• Myasthaenia Gravis

Interventions

Type	Name	Description
DRUG	Blinatumomab	The initial dose is 9 µ g, administered intravenously continuously for 5 days, with a total dose of 38.5 µ g. After stopping the medication for one week, the patient received a second infusion of Blinatumomab for a total of 5 days, with a total dose of 38.5 µ g.

Timeline

• Start date: 2024-11-30
• Primary completion: 2025-12-31
• Completion: 2026-06-30
• First posted: 2024-11-12
• Last updated: 2024-11-12

Regulatory

• FDA-regulated drug study